Quest Diagnostics Inc (NYSE:DGX) SVP Jon R. Cohen sold 83,669 shares of the stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $104.20, for a total value of $8,718,309.80. Following the sale, the senior vice president now directly owns 115,426 shares in the company, valued at $12,027,389.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Shares of Quest Diagnostics Inc (DGX) opened at $105.60 on Tuesday. Quest Diagnostics Inc has a 12 month low of $90.10 and a 12 month high of $112.96. The company has a market capitalization of $14,320.00, a PE ratio of 22.33, a PEG ratio of 1.92 and a beta of 0.68. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.15 and a current ratio of 1.24.
Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Thursday, February 1st. The medical research company reported $1.40 EPS for the quarter, beating the Zacks’ consensus estimate of $1.37 by $0.03. Quest Diagnostics had a return on equity of 15.41% and a net margin of 10.00%. The firm had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. During the same period last year, the firm posted $1.31 earnings per share. The business’s revenue for the quarter was up 4.0% on a year-over-year basis. sell-side analysts anticipate that Quest Diagnostics Inc will post 6.59 EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC acquired a new stake in shares of Quest Diagnostics during the third quarter valued at about $446,000. AXA boosted its stake in shares of Quest Diagnostics by 38.7% during the third quarter. AXA now owns 80,875 shares of the medical research company’s stock valued at $7,573,000 after purchasing an additional 22,575 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Quest Diagnostics by 4.7% during the third quarter. Schwab Charles Investment Management Inc. now owns 510,114 shares of the medical research company’s stock valued at $47,768,000 after purchasing an additional 22,798 shares in the last quarter. National Pension Service boosted its stake in shares of Quest Diagnostics by 9.5% during the fourth quarter. National Pension Service now owns 155,469 shares of the medical research company’s stock valued at $15,312,000 after purchasing an additional 13,460 shares in the last quarter. Finally, Acropolis Investment Management LLC boosted its stake in shares of Quest Diagnostics by 39.8% during the fourth quarter. Acropolis Investment Management LLC now owns 5,905 shares of the medical research company’s stock valued at $582,000 after purchasing an additional 1,682 shares in the last quarter. 88.65% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms recently weighed in on DGX. Argus raised Quest Diagnostics from a “hold” rating to a “buy” rating and raised their price objective for the company from $104.14 to $116.00 in a research note on Wednesday, March 7th. Zacks Investment Research lowered Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $110.00 price objective on shares of Quest Diagnostics in a research note on Thursday, February 1st. Goldman Sachs Group began coverage on Quest Diagnostics in a research note on Monday, January 29th. They issued a “buy” rating and a $117.00 price objective on the stock. Finally, Mizuho set a $113.00 price objective on Quest Diagnostics and gave the company a “buy” rating in a research note on Wednesday, January 24th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $108.10.
COPYRIGHT VIOLATION NOTICE: “Quest Diagnostics Inc (DGX) SVP Sells $8,718,309.80 in Stock” was originally posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3258745/quest-diagnostics-inc-dgx-svp-sells-8718309-80-in-stock.html.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.